The knee osteoarthritis market is experiencing rapid evolution driven by advancements in treatment modalities and increasing patient awareness globally. Industry dynamics highlight significant growth opportunities propelled by rising prevalence of osteoarthritis and innovations in biologic therapies. These factors collectively shape the competitive landscape and influence market growth strategies among leading companies.
Market Size and Overview
The knee osteoarthritis market is estimated to be valued at USD 13.19 Bn in 2025 and is expected to reach USD 30.46 Bn by 2032, growing at a compound annual growth rate (CAGR) of 12.7% from 2025 to 2032.
This Knee Osteoarthritis Market growth reflects expanding patient populations, enhanced diagnostic techniques, and increasing healthcare expenditure worldwide. With regulatory support and new product launches, the knee osteoarthritis market report underlines significant market scope and evolving market dynamics.
Market Segments
The knee osteoarthritis market encompasses product types, treatment approaches, and end-user categories. Key product type segments include viscosupplementation, corticosteroids, platelet-rich plasma (PRP), and novel biologics, where viscosupplementation currently dominates due to its efficacy in symptom relief. Meanwhile, biologics such as TLC599 by Taiwan Liposome Company are the fastest-growing sub-segment, capturing attention with promising clinical outcomes in 2024 trials. End users include hospitals, orthopedic clinics, and outpatient surgical centers; of these, outpatient centers experienced fastest growth in 2025 owing to increased adoption of minimally invasive procedures and outpatient care trends. Application-wise, early-stage osteoarthritis treatment and pain management are core segments, with early intervention therapies demonstrating accelerated growth driven by patient preference for non-surgical options.
Market Drivers
A major driver propelling knee osteoarthritis market growth is the surge in geriatric populations with lifestyle-related risk factors such as obesity and sedentary behavior. In 2024, over 30% of adults aged 60+ globally were diagnosed with knee osteoarthritis, fueling demand for advanced therapeutic options. Additionally, supportive government healthcare policies aimed at improving musculoskeletal health, coupled with increased reimbursement for biologics and viscosupplementation injections, are catalyzing market expansion. The introduction of next-generation products like CNTX-4975 by Centrexion Therapeutics in 2025 significantly added momentum to the knee osteoarthritis market trends.
Segment Analysis: Product Type
Focusing on product type, viscosupplementation accounted for the highest market revenue in 2024, owing to its established safety profile and widespread clinical adoption. Concurrently, biologics are the fastest-growing segment, with an estimated growth rate exceeding 18% year-on-year, as evidenced by ongoing Phase III trials and regulatory fast-tracking of innovative therapeutics. For instance, Sanofi/Genzyme’s pipeline biologics demonstrated promising patient-reported outcomes in 2025 clinical evaluations, reflecting a shift towards personalized treatment paradigms within the knee osteoarthritis market analysis.
Consumer Behaviour Insights
Recent insights from 2024–2025 indicate decisive shifts in consumer behavior in the knee osteoarthritis arena. Increasing digital healthcare consumption has led patients to seek virtual consultations and telemedicine for early diagnosis and treatment planning. Pricing sensitivity remains prominent, with a preference for cost-effective therapies that offer rapid pain relief and functional improvement. Additionally, customization trends have accelerated, with patients and physicians demanding tailored treatment regimes incorporating biologics, which aligns with broader patient-centric care models. A 2025 survey revealed 65% of osteoarthritis patients prioritize treatment personalization and minimally invasive options, emphasizing sustainability preferences in therapeutic choices.
Key Players
The knee osteoarthritis market features prominent players such as Anika Therapeutics, Bioventus, Sanofi/Genzyme, Taiwan Liposome Company (TLC599), Centrexion Therapeutics (CNTX-4975), and more. Throughout 2024 and 2025, these market companies leveraged growth strategies including innovative product launches, geographic expansions especially in Asia-Pacific regions, and strategic partnerships for R&D acceleration. Anika Therapeutics expanded its production capacity in early 2025 to meet surging demand for hyaluronic acid-based injections, while Bioventus enhanced its biologics portfolio with multiple approvals across Europe and North America, directly influencing market revenue growth.
Key Winning Strategies Adopted by Key Players
Some of the most impactful strategies include Taiwan Liposome Company’s focus on molecule delivery enhancement for TLC599 in 2024, which improved drug bioavailability and extended therapeutic effect duration, addressing a critical market challenge of injection frequency. Centrexion Therapeutics’ 2025 breakthrough with CNTX-4975’s novel delivery method reduced adverse effects, positioning it as a preferred injectable analgesic, thereby boosting patient compliance. Additionally, Sanofi/Genzyme’s investment in digital therapeutics and remote patient monitoring solutions introduced in late 2024 exemplifies integration of technology into treatment, leveraging data analytics to personalize care, a strategy especially relevant for informed expert readers seeking actionable market growth strategies.
FAQs
Q1: Who are the dominant players in the knee osteoarthritis market?
A1: Leading market players include Anika Therapeutics, Bioventus, Sanofi/Genzyme, Taiwan Liposome Company, and Centrexion Therapeutics, known for their innovative product pipelines and strategic expansions between 2024 and 2025.
Q2: What will be the size of the knee osteoarthritis market in the coming years?
A2: The market is expected to grow from USD 13.19 billion in 2025 to USD 30.46 billion by 2032, with a CAGR of 13%, driven by rising disease incidence and new therapeutic developments.
Q3: Which end-user industry has the largest growth opportunity?
A3: Outpatient surgical centers and orthopedic clinics are witnessing the fastest growth, attributable to minimally invasive treatment adoption and improved accessibility in 2025.
Q4: How will market development trends evolve over the next five years?
A4: Trends indicate heightened adoption of biologics and personalized therapies, increased digital healthcare integration, and expansion of reimbursement frameworks facilitating market growth.
Q5: What is the nature of the competitive landscape and challenges in the knee osteoarthritis market?
A5: The landscape is competitive with rapid innovation pipelines; challenges include managing treatment costs and ensuring patient adherence to minimally invasive therapies.
Q6: What go-to-market strategies are commonly adopted in the knee osteoarthritis market?
A6: Key strategies include capacity expansions, focus on research collaborations for biologics, and incorporation of digital monitoring solutions, as showcased by major companies during 2024–2025.
‣ Get more insights on : Knee Osteoarthritis Market
‣ Get this Report in Japanese Language : 膝関節炎市場
‣ Get this Report in Korean Language : 무릎골관절염시장
‣ Read More Related Articles Ankle Fusion Surgery: A Revolutionary Procedure to Fix Ankle Problem
Author Bio
Vaagisha brings over three years of expertise as a content editor in the market research domain. Originally a creative writer, she discovered her passion for editing, combining her flair for writing with a meticulous eye for detail. Her ability to craft and refine compelling content makes her an invaluable asset in delivering polished and engaging write-ups.(LinkedIn: https://www.linkedin.com/in/vaagisha-singh-8080b91)